Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) EBITDA Margin (2018 - 2025)

Bicycle Therapeutics' EBITDA Margin history spans 8 years, with the latest figure at 42.1% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 126723.0% year-over-year to 42.1%; the TTM value through Dec 2025 reached 306.65%, up 33442.0%, while the annual FY2025 figure was 306.65%, 16850.0% up from the prior year.
  • EBITDA Margin reached 42.1% in Q4 2025 per BCYC's latest filing, up from 504.58% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 42.1% in Q4 2025 to a low of 2768.97% in Q2 2025.
  • Average EBITDA Margin over 5 years is 829.36%, with a median of 747.29% recorded in 2023.
  • The largest YoY upside for EBITDA Margin was 147206bps in 2025 against a maximum downside of -234032bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 1139.5% in 2021, then soared by 69bps to 358.56% in 2022, then crashed by -179bps to 999.59% in 2023, then crashed by -31bps to 1309.33% in 2024, then surged by 97bps to 42.1% in 2025.
  • Per Business Quant, the three most recent readings for BCYC's EBITDA Margin are 42.1% (Q4 2025), 504.58% (Q3 2025), and 2768.97% (Q2 2025).